BIG
NVCR icon

Brooklyn Investment Group’s NovoCure NVCR Stock Holding History

Brooklyn Investment Group’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-2,923
Closed -$52K – 2008
2025
Q2 		$52K Buy
2,923
+28
+1% +$488 0.01% 1317
2025
Q1 		$51.6K Sell
2,895
-18
-0.6% -$409 0.01% 766
2024
Q4 		$86.8K Buy
2,913
+13
+0.4% +$275 0.03% 395
2024
Q3 		$45.3K Buy
+2,900
New +$52.6K 0.01% 496

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
QCM
Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Brooklyn Investment Group's NVCR Position: Q3 2025 in Review

Brooklyn Investment Group sold out of NovoCure (NVCR) in Q3 2025, closing a stake of 2,923 shares — an estimated $52K sold.

Brooklyn Investment Group first reported a position in NVCR in Q3 2024 and held it in 4 quarters. The position peaked at $86.8K in Q4 2024. 244 funds tracked by Wall St. Rank hold NVCR as of Q3 2025.

  • Brooklyn Investment Group reported no remaining NovoCure position as of Q3 2025 after selling out during the quarter.
  • Brooklyn Investment Group sold 2,923 NovoCure shares in Q3 2025, an estimated $52K.
  • Brooklyn Investment Group first reported a position in NovoCure in Q3 2024 and held it in 4 quarters.
  • Brooklyn Investment Group's NovoCure position peaked at $86.8K in Q4 2024.
  • 244 funds tracked by Wall St. Rank held NovoCure as of Q3 2025.

Based on Brooklyn Investment Group's 13F filing for Q3 2025, filed 14 Nov 2025.